3
Announcements
Trials
Browse
Landscape
Status
Approved for marketing
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
78
Expanded_access
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma, Mantle-Cell
1
Leukemia
1
Immunoproliferative Disorders
1
Immune System Diseases
1
Hodgkin Disease
1
Interventions
3-Iodobenzylguanidine
3
talquetamab
2
ibrutinib
2
zanubrutinib
1
vorasidenib
1
sugemalimab
1
revumenib
1
pomalidomide
1
loncastuximab tesirine
1
fludarabine phosphate
1
fludarabine
1
denileukin diftitox
1
brexucabtagene autoleucel
1
axicabtagene ciloleucel
1
Whole-Body Irradiation
1
Tacrolimus
1
Panobinostat
1
Mycophenolic Acid
1
Immunotherapy, Adoptive
1
Cytarabine
1
Cyclophosphamide
1
Cord Blood Stem Cell Transplantation
1
Busulfan
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Expanded_access
×
Recurrence
×
fludarabine
×
Clear all
NCT04162756
2021-10-14
ZUMA-18
Gilead Sciences
Approved for marketing